CCR7 and cancer: Finally, it is worth to indicate that anti-CCR7 therapy in pre-clinical syngeneic mouse models of cancer, autoimmunity, GVHD, or inflammation did not uncover un-wanted treatment-associated side effects (184, 223, 229) and CAP-100 toxicology studies in NHP did not reveal overt toxicities or autoimmune disease indicating tolerability of this novel therapy.